Compare · MDT vs NXL
MDT vs NXL
Side-by-side comparison of Medtronic plc. (MDT) and Nexalin Technology Inc. (NXL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and NXL operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $117.81B, about 20888.5x NXL ($5.6M).
- MDT has been more active in the news (10 items in the past 4 weeks vs 8 for NXL).
- MDT has more recent analyst coverage (25 ratings vs 0 for NXL).
- Company
- Medtronic plc.
- Nexalin Technology Inc.
- Price
- -
- -
- Market cap
- $117.81B
- $5.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 10
- 8
- Recent ratings
- 25
- 0
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest MDT
- Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance
- Medtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted Surgery
- Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR
- Needham reiterated coverage on Medtronic with a new price target
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 1,084 units of Ordinary Shares, decreasing direct ownership by 0.92% to 116,336 units (SEC Form 4)
- Medtronic announces cash dividend for second quarter of fiscal year 2027
- SEC Form DEFA14A filed by Medtronic plc.
- SEC Form DEF 14A filed by Medtronic plc.
- Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
Latest NXL
- Nexalin Technology Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Nexalin Technology Announces Reverse Stock Split
- Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 424B5 filed by Nexalin Technology Inc.
- Nexalin Technology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-Q filed by Nexalin Technology Inc.
- SEC Form 8-K filed by Nexalin Technology Inc.
- Nexalin Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Nexalin Technology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing